Atmofizer Technologies（ATMO）株式概要Atmofizer Technologies Inc.は、米国でクリーンな空気と水のソリューションを提供している。 詳細ATMO ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6報酬過去5年間の収益は年間6.5%増加しました。 リスク分析キャッシュランウェイが1年未満である マイナスの株主資本 収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( CA$475K )+1 さらなるリスクすべてのリスクチェックを見るATMO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.055該当なし内在価値ディスカウントEst. Revenue$PastFuture-28m497k2016201920222025202620282031Revenue US$0.3Earnings US$0.03AdvancedSet Fair ValueView all narrativesAtmofizer Technologies Inc. 競合他社Forward Water TechnologiesSymbol: TSXV:FWTCMarket cap: CA$2.3mReko International GroupSymbol: TSXV:REKOMarket cap: CA$24.4mEnWaveSymbol: TSXV:ENWMarket cap: CA$28.5mOmni-Lite Industries CanadaSymbol: TSXV:OMLMarket cap: CA$30.0m価格と性能株価の高値、安値、推移の概要Atmofizer Technologies過去の株価現在の株価CA$0.05552週高値CA$0.2052週安値CA$0.02ベータ0.981ヶ月の変化0%3ヶ月変化-8.33%1年変化-26.67%3年間の変化-93.13%5年間の変化n/aIPOからの変化-99.94%最新ニュースお知らせ • Jun 10Atmofizer Technologies Inc. announced that it expects to receive CAD 0.5 million in fundingAtmofizer Technologies Inc. announced a non-brokered private placement of Zero Coupon unsecured convertible debentures for aggregate gross proceeds of up to CAD 500,000 on June 9, 2026. The transaction is expected to close on or about June 15, 2026. The Company may complete one or more closings of additional tranches in the coming weeks and may upsize the Financing in its sole discretion. The Convertible Debentures are unsecured, do not bear interest, and mature on the earlier of (i) ten (10) business days following closing of the previously announced proposed reverse takeover transaction between Atmofizer and Power Leaves Corp. (“PLC”) (the “Proposed Transaction”) or (ii) December 31, 2026. Each Resulting Issuer Unit will be comprised of one common share of the Resulting Issuer and one common share purchase warrant, with each warrant exercisable into one additional common share of the Resulting Issuer at a price of CAD 0.42 for a period of 24 months from closing of the Proposed Transaction. The Convertible Debentures are expected to be qualified investments for registered plans under the Income Tax Act (Canada), subject to the specific circumstances of each investor. The Convertible Debentures and any securities issuable upon conversion thereof will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.お知らせ • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.最新情報をもっと見るRecent updatesお知らせ • Jun 10Atmofizer Technologies Inc. announced that it expects to receive CAD 0.5 million in fundingAtmofizer Technologies Inc. announced a non-brokered private placement of Zero Coupon unsecured convertible debentures for aggregate gross proceeds of up to CAD 500,000 on June 9, 2026. The transaction is expected to close on or about June 15, 2026. The Company may complete one or more closings of additional tranches in the coming weeks and may upsize the Financing in its sole discretion. The Convertible Debentures are unsecured, do not bear interest, and mature on the earlier of (i) ten (10) business days following closing of the previously announced proposed reverse takeover transaction between Atmofizer and Power Leaves Corp. (“PLC”) (the “Proposed Transaction”) or (ii) December 31, 2026. Each Resulting Issuer Unit will be comprised of one common share of the Resulting Issuer and one common share purchase warrant, with each warrant exercisable into one additional common share of the Resulting Issuer at a price of CAD 0.42 for a period of 24 months from closing of the Proposed Transaction. The Convertible Debentures are expected to be qualified investments for registered plans under the Income Tax Act (Canada), subject to the specific circumstances of each investor. The Convertible Debentures and any securities issuable upon conversion thereof will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.お知らせ • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.お知らせ • Aug 26Atmofizer Technologies Inc. Announces Latest Independent Test ResultsAtmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors. Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.お知らせ • May 12Atmofizer Technologies Inc. Announces Latest Test Data and Expansion of Research and Testing Team in Toronto LabAtmofizer Technologies Inc. announce the Company's test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer'sToronto lab have shown the Company's technology, before the use of an air filter, reduced the number of airborne ultra-fine particles smaller than one micron by 81.7%, while doubling particles sized above 2.5 microns. The Company says this is significant scientifically and medically, as it shows the removal of the smallest nanoscopic airborne particles (including toxic industrial pollution, smoke, and infectious disease). These particles are small enough that they can enter the bloodstream and get into the brain and vital organs directly through being inhaled into the lungs. Particles smaller than 2.5 microns are commonly regarded as the measure of air quality because they pose the risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that the smaller particles are effectively being agglomerated together into larger clusters by the Company's technology. These larger clusters are typically more easily filtered by the body and common air filters. It is also significant that these results were without the use of a filter. The Company has also added additional staff to its Toronto testing facility to focus on applying its agglomeration technology into mobile (transport vehicles) and HVAC aftermarket applications. The additional staff will enable the Company to test and evaluate new Atmofizer airflow configurations and prototypes more quickly.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. Independent Director Michael Galloro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 18Kemper Confirms Successful Test of Atmofizer Technology Improving Industrial Fume ExtractionAtmofizer Technologies Inc. announced the completion of initial tests by Kemper GmbH. The air purification industry has largely focused on developing new filters that catch smaller particles. The challenge is that the tighter the filters the more energy is required to push air through and the most performant filters, HEPA are not recyclable or reusable so they end up in the landfills. Atmofizer's technology works by using ultrasonic waves to agglomerate the smallest particles into larger clusters to more effectively filter and neutralize harmful particles using ultraviolet light. The mission of Atmofizer is to bring clean air and water to the world.お知らせ • Jan 06Atmofizer Technologies Inc. Announces Indoor Agriculture Testing for Mold ReductionAtmofizer Technologies Inc. announced that, following a pilot project, Atmofizer will begin secondary testing of its agglomeration technology with SANlight products in Austria. Atmofizer's technology uses proprietary sound wave technology to agglomerate microscopic airborne particles making them easier to capture and neutralize with UV light. SANlight is a leader in LED lighting technology for indoor gardening (better: horticultural LED lighting).お知らせ • Dec 29Atmofizer to Release Its Latest "Back-To-Work" Product SolutionAtmofizer Technologies Inc. announced that it will attend the 2022 Consumer Electronics Show in Las Vegas, Nevada. The Company will be located at booth #52946 in The Venetian Convention and Expo Center from January 4, 2022 until January 8, 2022. Atmofizer intends to use the CES stage to release its latest "back-to-work" product solution, connect with new distributors and collaborate with integrators, including some of the world's largest appliance manufacturers.Recent Insider Transactions • Dec 03Insider recently sold CA$5.0m worth of stockOn the 29th of November, Catherine Defrancesco sold around 986k shares on-market at roughly CA$5.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$4.8m more than they bought in the last 12 months.お知らせ • Dec 01Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO).Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021. As part of the agreement, Catherine Brewer DeFrancesco acquired 6.05 million common shares of Atmofizer Technologies. Prior to the acquisition, Brewer DeFrancesco had control and direction over an aggregate of 2.848 million common shares. The aggregate 8.898 million common shares now controlled and directed by Brewer DeFrancesco represents approximately 12.04% of the issued and outstanding common shares on a non-diluted basis of Atmofizer Technologies. Catherine Brewer DeFrancesco completed the acquisition of 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021.Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元ATMOCA MachineryCA 市場7D0%0.8%-1.8%1Y-26.7%8.2%30.6%株主還元を見る業界別リターン: ATMO過去 1 年間で8.2 % の収益を上げたCanadian Machinery業界を下回りました。リターン対市場: ATMOは、過去 1 年間で30.6 % のリターンを上げたCanadian市場を下回りました。価格変動Is ATMO's price volatile compared to industry and market?ATMO volatilityATMO Average Weekly Movementn/aMachinery Industry Average Movement8.1%Market Average Movement9.8%10% most volatile stocks in CA Market16.4%10% least volatile stocks in CA Market3.7%安定した株価: ATMOの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のATMOのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aOlivier Centnerwww.atmofizer.comAtmofizer Technologies Inc.は、米国でクリーンな空気と水のソリューションを提供している。同社はビジネス、消費者、医療、産業用アプリケーション向けの技術の商業化に注力している。本社はカナダのバンクーバー。もっと見るAtmofizer Technologies Inc. 基礎のまとめAtmofizer Technologies の収益と売上を時価総額と比較するとどうか。ATMO 基礎統計学時価総額CA$475.25k収益（TTM）-CA$337.68k売上高(TTM)n/a0.0xP/Sレシオ-1.4xPER（株価収益率ATMO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ATMO 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$245.68k収益-US$245.68k直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.028グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-16.7%ATMO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/27 10:23終値2025/02/27 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Atmofizer Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Peter-Thilo HaslerSphene Capital GmbH
お知らせ • Jun 10Atmofizer Technologies Inc. announced that it expects to receive CAD 0.5 million in fundingAtmofizer Technologies Inc. announced a non-brokered private placement of Zero Coupon unsecured convertible debentures for aggregate gross proceeds of up to CAD 500,000 on June 9, 2026. The transaction is expected to close on or about June 15, 2026. The Company may complete one or more closings of additional tranches in the coming weeks and may upsize the Financing in its sole discretion. The Convertible Debentures are unsecured, do not bear interest, and mature on the earlier of (i) ten (10) business days following closing of the previously announced proposed reverse takeover transaction between Atmofizer and Power Leaves Corp. (“PLC”) (the “Proposed Transaction”) or (ii) December 31, 2026. Each Resulting Issuer Unit will be comprised of one common share of the Resulting Issuer and one common share purchase warrant, with each warrant exercisable into one additional common share of the Resulting Issuer at a price of CAD 0.42 for a period of 24 months from closing of the Proposed Transaction. The Convertible Debentures are expected to be qualified investments for registered plans under the Income Tax Act (Canada), subject to the specific circumstances of each investor. The Convertible Debentures and any securities issuable upon conversion thereof will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
お知らせ • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.
Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.
お知らせ • Jun 10Atmofizer Technologies Inc. announced that it expects to receive CAD 0.5 million in fundingAtmofizer Technologies Inc. announced a non-brokered private placement of Zero Coupon unsecured convertible debentures for aggregate gross proceeds of up to CAD 500,000 on June 9, 2026. The transaction is expected to close on or about June 15, 2026. The Company may complete one or more closings of additional tranches in the coming weeks and may upsize the Financing in its sole discretion. The Convertible Debentures are unsecured, do not bear interest, and mature on the earlier of (i) ten (10) business days following closing of the previously announced proposed reverse takeover transaction between Atmofizer and Power Leaves Corp. (“PLC”) (the “Proposed Transaction”) or (ii) December 31, 2026. Each Resulting Issuer Unit will be comprised of one common share of the Resulting Issuer and one common share purchase warrant, with each warrant exercisable into one additional common share of the Resulting Issuer at a price of CAD 0.42 for a period of 24 months from closing of the Proposed Transaction. The Convertible Debentures are expected to be qualified investments for registered plans under the Income Tax Act (Canada), subject to the specific circumstances of each investor. The Convertible Debentures and any securities issuable upon conversion thereof will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
お知らせ • Apr 28Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026Atmofizer Technologies Inc., Annual General Meeting, Jun 23, 2026.
Board Change • Dec 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Michael Galloro was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 11High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 27Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022Atmofizer Technologies Inc., Annual General Meeting, Nov 25, 2022.
お知らせ • Aug 26Atmofizer Technologies Inc. Announces Latest Independent Test ResultsAtmofizer Technologies Inc. announced the latest testing performed by a third-party laboratory on Atmofizer ONE technology demonstrated a greater than 4-log reduction (> 99.99%) in specifically targeted microorganisms, including gram-positive bacteria, gram-negative bacteria, and enveloped virus. The Atmofizer ONE is now marketed subject to the U.S. Food and Drug Administration's "Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency" (March 2020). Atmofizer's patented agglomeration technology is designed to: Aggregate airborne nanoparticles into more-addressable particulates; Use acoustic pressure to cluster the smallest airborne particulates and microorganisms, before exposure to ultraviolet light, Increase the size of airborne ultra-fine particles, Not emit ozone, or use ionization, Reduce household odors. Atmofizer ONE Performance Update: Atmofizer Efficacy Claims: 99.99% reduction of Klebsiella Aerogenes [gram-negative bacteria], 99.99% reduction of Staphylococcus Epidermis [gram-positive bacteria], 99.99% reduction of Phi-6 Bacteriophage [enveloped virus, Surrogate for SARS-CoV-2]. Atmofizer SARS-CoV-2 Specific Efficacy Claims: Atmofizer reduces airborne SARS-CoV-2, Atmofizer destroys over 99.99% SARS-CoV-2 without a filter, Atmofizer destroys SARS-CoV-2 by over 99.99% in 45 minutes. These results are based on third-party laboratory tests at 180 minutes of continuous device operation. The Food and Drug Administration (FDA) has not evaluated Atmofizer technology. Atmofizer ONE has not been reviewed or approved by the FDA. SARS-CoV-2 data is based on Third-Party Testing of Phi-6 Bacteriophage, a surrogate microorganism for SARS-CoV-2.
お知らせ • May 12Atmofizer Technologies Inc. Announces Latest Test Data and Expansion of Research and Testing Team in Toronto LabAtmofizer Technologies Inc. announce the Company's test results of its airborne nanoparticle agglomeration engine. Recent test results at Atmofizer'sToronto lab have shown the Company's technology, before the use of an air filter, reduced the number of airborne ultra-fine particles smaller than one micron by 81.7%, while doubling particles sized above 2.5 microns. The Company says this is significant scientifically and medically, as it shows the removal of the smallest nanoscopic airborne particles (including toxic industrial pollution, smoke, and infectious disease). These particles are small enough that they can enter the bloodstream and get into the brain and vital organs directly through being inhaled into the lungs. Particles smaller than 2.5 microns are commonly regarded as the measure of air quality because they pose the risk to humans and animals. Doubling the amount of particles above 2.5 microns shows that the smaller particles are effectively being agglomerated together into larger clusters by the Company's technology. These larger clusters are typically more easily filtered by the body and common air filters. It is also significant that these results were without the use of a filter. The Company has also added additional staff to its Toronto testing facility to focus on applying its agglomeration technology into mobile (transport vehicles) and HVAC aftermarket applications. The additional staff will enable the Company to test and evaluate new Atmofizer airflow configurations and prototypes more quickly.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Peter Simeon is the most experienced director on the board, commencing their role in 2020. Independent Director Michael Galloro was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 18Kemper Confirms Successful Test of Atmofizer Technology Improving Industrial Fume ExtractionAtmofizer Technologies Inc. announced the completion of initial tests by Kemper GmbH. The air purification industry has largely focused on developing new filters that catch smaller particles. The challenge is that the tighter the filters the more energy is required to push air through and the most performant filters, HEPA are not recyclable or reusable so they end up in the landfills. Atmofizer's technology works by using ultrasonic waves to agglomerate the smallest particles into larger clusters to more effectively filter and neutralize harmful particles using ultraviolet light. The mission of Atmofizer is to bring clean air and water to the world.
お知らせ • Jan 06Atmofizer Technologies Inc. Announces Indoor Agriculture Testing for Mold ReductionAtmofizer Technologies Inc. announced that, following a pilot project, Atmofizer will begin secondary testing of its agglomeration technology with SANlight products in Austria. Atmofizer's technology uses proprietary sound wave technology to agglomerate microscopic airborne particles making them easier to capture and neutralize with UV light. SANlight is a leader in LED lighting technology for indoor gardening (better: horticultural LED lighting).
お知らせ • Dec 29Atmofizer to Release Its Latest "Back-To-Work" Product SolutionAtmofizer Technologies Inc. announced that it will attend the 2022 Consumer Electronics Show in Las Vegas, Nevada. The Company will be located at booth #52946 in The Venetian Convention and Expo Center from January 4, 2022 until January 8, 2022. Atmofizer intends to use the CES stage to release its latest "back-to-work" product solution, connect with new distributors and collaborate with integrators, including some of the world's largest appliance manufacturers.
Recent Insider Transactions • Dec 03Insider recently sold CA$5.0m worth of stockOn the 29th of November, Catherine Defrancesco sold around 986k shares on-market at roughly CA$5.10 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of CA$4.8m more than they bought in the last 12 months.
お知らせ • Dec 01Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO).Catherine Brewer DeFrancesco acquired 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021. As part of the agreement, Catherine Brewer DeFrancesco acquired 6.05 million common shares of Atmofizer Technologies. Prior to the acquisition, Brewer DeFrancesco had control and direction over an aggregate of 2.848 million common shares. The aggregate 8.898 million common shares now controlled and directed by Brewer DeFrancesco represents approximately 12.04% of the issued and outstanding common shares on a non-diluted basis of Atmofizer Technologies. Catherine Brewer DeFrancesco completed the acquisition of 8.2% stake in Atmofizer Technologies Inc. (CNSX:ATMO) on November 22, 2021.
Board Change • Nov 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
